Shire has hit the acquisition trail and is spending $4.20 billion to buy the US rare disease specialist ViroPharma.
The Ireland-headquartered group is paying $50 per share, which represents a 27% premium on ViroPharma's closing share price on November 8. The deal gives Shire access to the hereditary angioedema drug Cinryze (C1 inhibitor [human]), which complements its own HAE drug Firazyr (icatibant).
http://www.pharmatimes.com/Article/13-11-11/Shire_acquires_ViroPharma_for_4_20_billion.aspx?
The Ireland-headquartered group is paying $50 per share, which represents a 27% premium on ViroPharma's closing share price on November 8. The deal gives Shire access to the hereditary angioedema drug Cinryze (C1 inhibitor [human]), which complements its own HAE drug Firazyr (icatibant).
http://www.pharmatimes.com/Article/13-11-11/Shire_acquires_ViroPharma_for_4_20_billion.aspx?
No comments:
Post a Comment